SDGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SDGR is not a good buy right now for an impatient entry. The stock is in a strong, accelerating downtrend (bearish MAs + expanding negative MACD) despite being extremely oversold (RSI~13.7). That combination can bounce, but it’s statistically unreliable timing without a confirmed reversal or a proprietary entry signal. If you must act immediately, this is closer to a speculative mean-reversion attempt than a high-conviction buy; the higher-probability play is to hold off and reassess after stabilization or into the 2026-02-26 earnings catalyst.
Trend is bearish and deteriorating: SMA_200 > SMA_20 > SMA_5 confirms a sustained downtrend. Momentum is negative with MACD histogram at -0.393 and negatively expanding (selling pressure increasing). RSI_6 at 13.68 is deeply oversold, which raises the odds of a short-term bounce, but oversold can persist in downtrends. Key levels: current price 13.705 is below Pivot 15.652 and near support band S1 13.962 / S2 12.919 (price is already under S1, so S2 ~12.92 is the next notable downside level). Upside rebound targets (if a bounce occurs) would likely face resistance at ~15.65 (pivot) then ~17.34 (R1). Pattern-based projection provided: ~60% chance of -0.91% next day, +1.74% next week, +6.45% next month—suggesting near-term chop/down before a potential multi-week recovery.
Intellectia Proprietary Trading Signals
Analyst targets remain well above the current price (recent targets $18–$25 vs ~$13.7), which can support rebound narratives if execution holds.
Revenue growth is strong (2025/Q3 +53.94% YoY), supporting the "inflection" storyline some analysts cite.
Upcoming earnings: QDEC 2025 earnings on 2026-02-26 (After Hours) can act as a catalyst if guidance improves or margins/expense control surprises positively.
Options open interest skew (very low OI put-call) suggests the market is not heavily positioned for deep downside on a longer-dated basis.
Price action is decisively bearish (bearish MA stack + expanding negative MACD) and the stock is breaking below nearby support (below S1 ~13.96), raising the risk of a continuation move toward ~12.92 (S2).
Losses remain significant: net income is more negative YoY and EPS declined YoY, which can keep pressure on valuation and sentiment in risk-off tape.
Macro tape: SP500 down on the session (-0.72%) while SDGR is down more (-4.19%), signaling relative weakness.
News flow provided is not directly SDGR-specific (mostly VentriPoint/AI imaging market commentary), so there’s no clear near-term company-specific positive trigger from the supplied headlines.
Latest reported quarter provided: 2025/Q3. Revenue increased to $54.324M (+53.94% YoY), indicating strong top-line momentum. Profitability remains weak: net income fell to -$32.795M (more negative; -14.01% YoY), and EPS declined to -0.45 (-13.46% YoY). Gross margin improved to 51.61% (+2.73% YoY), which is a constructive sign, but operating losses still dominate—so the market may require evidence of improving expense discipline and a clearer path to narrowing losses. Next earnings: QDEC 2025 on 2026-02-26 (After Hours).
Recent Wall Street trend is mixed but broadly supportive on long-term upside, with some target cuts:
Pros view (bull case): strong revenue growth, improving gross margin, and a sector backdrop that could improve in 2026; multiple firms see meaningful upside vs current price. Cons view (bear case): several firms cut price targets (even while maintaining positive ratings), implying tempered confidence/valuation pressure; near-term stock trend is weak and profitability remains a key overhang.
Influential/politician activity: No recent congress trading data available in the last 90 days; hedge fund and insider trend signals are neutral with no significant recent activity flagged.
